MT-304

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameMT-304
Drug Alias NameMT-304
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Somatic cell > Myeloid cells‌ > Chimeric antigen receptor myeloid cellsCell and gene therapy > Gene therapy > mRNA +[4] 
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCREATE Medicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesCREATE Medicines IncMyeloid Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A